Featured Post

Community-Acquired Pneumonia (CAP)

Image
pulmonary venous hypertension :: Article Creator Insmed Stock Soars On Pulmonary Arterial Hypertension Drug Trial Results Shares of Insmed (INSM) jumped nearly 30% Tuesday after the biopharmaceutical company reported positive results from a Phase 2 trial for its treatment of pulmonary arterial hypertension. The Bridgewater, N.J.-based company said the study was "evaluating the efficacy and safety of treprostinil palmitil inhalation powder" in patients with pulmonary arterial hypertension, or PAH, and that the trial "met its primary endpoint and all secondary efficacy endpoints." Pulmonary hypertension, which develops when the blood pressure in your lungs is higher than normal, affects about 1% of people globally, per the National Heart, Lung, and Blood Institute. Insmed said it would "immediately engage with the U.S. Food and Drug Administration (FDA) regarding the Phase 3 trial design for PAH. Insmed plans to in...

Daily coronavirus updates: Positive infection rate climbs to highest level in Connecticut since April as delta variant surge continues; hospitalizations, deaths increase - Hartford Courant

Unfortunately, our website is currently unavailable in your country. We are engaged on the issue and committed to looking at options that support our full range of digital offerings to your market. We continue to identify technical compliance solutions that will provide all readers with our award-winning journalism.

Adblock test (Why?)

Comments

Popular Posts

Model Monday's: Diana Moldovan

“Teaching a pandemic in real time, part 2 . Princeton professors share how they incorporate the study - Princeton University” plus 1 more

Preventing, controlling spread of animal diseases focus of forum at Penn State - Pennsylvania State University